NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Tuesday that its second quarter revenues more than doubled year over year thanks in large part to a 160 percent increase in the number of Cologuard colorectal cancer screening tests completed during the quarter.

For the three months ended June 30, the molecular diagnostics firm reported revenues of $21.2 million, up from $8.1 million a year ago, and beating the consensus Wall Street estimate of $18.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.